Adjuvant chemotherapy of resistant high risk choriocarcinoma

Tamara Đuričić; Aljoša Mandić; Bojana Gutić; Nataša Prvulović Bunović; Nevena Stanulović

doi:10.2298/AOO200408005D

Tamara Đuričić Oncology Institute of Vojvodina, Put dr Goldmana 4, 21204 Sremska Kamenica
Aljoša Mandić Oncology Institute of Vojvodina, Put Dr Goldmana 4, 21204 Sremska Kamenica; University of Novi Sad, Faculty of Medicine, Hajduk Veljkova 3, 21000 Novi Sad
Bojana Gutić Oncology Institute of Vojvodina, Put Dr Goldmana 4, 21204 Sremska Kamenica; University of Novi Sad, Faculty of Medicine, Hajduk Veljkova 3, 21000 Novi Sad
Nataša Prvulović Bunović Oncology Institute of Vojvodina, Put Dr Goldmana 4, 21204 Sremska Kamenica; University of Novi Sad, Faculty of Medicine, Hajduk Veljkova 3, 21000 Novi Sad
Nevena Stanulović Oncology Institute of Vojvodina, Put dr Goldmana 4, 21204 Sremska Kamenica

DOI: https://doi.org/10.2298/AOO200408005D

Keywords: gestational trophoblastic disease, chemotherapy, choriocarcinoma

Abstract

SUMMARY

Choriocarcinoma is a subtype of gestational trophoblastic disease. It is a very rare neoplasm, with incidence of about 1 case in 40.000 pregnancies. Gestational form of choriocarcinoma arises most commonly after abortion, while non-gestational form develops from pluripotent germ cells. Choricarcinoma is highly malignant and highly chemosensitive type of tumor.

A 43-year-old patient diagnosed with extra uterine pregnancy in September 2017 was treated with Methotrexate with no response and had surgical removal of right Fallopian tube. Choriocarcinoma was diagnosed one and a half year after extra uterine pregnancy. Radiological imaging before treatment showed pulmonary and inguinal lymph node metastases and tumor invasion of the anterior uterine wall. Surgery was performed due to heavy bleeding and uterine wall invasion. As high risk patient she received chemotherapy. She was followed radiologically and her serum β-HCG was monitored. Refractivity to the chemotherapy protocol during treatment was observed. Therapy response was achieved after administration of EMA-EP protocol modification i.e. three consecutive negative follow-up values of β-HCG were obtained and radiological findings were disease free. One month after treatment patient had no signs of disease and β-HCG level was normal.

References

Bishop BN, Edemekong PF. Choriocarcinoma. In: StatPearls. StatPearls Publishing, Treasure Island (FL); 2019.

Lurain JR. Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. Am. J. Obstet. Gynecol. 2010 Dec;203(6):531-9.

Stockton L, Green E, Kaur B, De Winton E. Non-Gestational Choriocarcinoma with Widespread Metastases Presenting with Type 1 Respiratory Failure in a 39-Year-Old Female: Case Report and Review of the Literature. Case Rep Oncol. 2018 Jan-Apr;11(1):151-158.

Zhang W, Liu B, Wu J, Sun B. Hemoptysis as primary manifestation in three women with choriocarcinoma with pulmonary metastasis: a case series. J Med Case Rep. 2017 Apr 16;11(1):110.

Lurain JR. Gestational trophoblastic disease II: classification and management of gestational trophoblastic neoplasia. Am. J. Obstet. Gynecol. 2011 Jan;204(1):11-8.

FIGO Oncology Committee. FIGO staging for gestational trophoblastic neoplasia 2000. International Journal of Gynecology & Obstetrics 77:285-287.

Seckl M.J., Sebire N.J., Fisher R.A., Golfier F., Massuger L., Sessa C. Gestational trophoblastic disease: ESMO clinical practice guidelines for diagnosis, treatment and follow-up (2013) Annals of Oncology, 24 (SUPPL.6) , art. no. mdt345 , pp. vi39-vi50.

Meddeb, S., Rhim, M. S., Zarrouk, W., Bibi, M., Yacoubi, M. T., & Khairi, H. (2014). Unusual gestational choriocarcinoma arising in an interstitial pregnancy. International Journal of Surgery Case Reports, 5(11), 787-788. doi:10.1016/j.ijscr.2014.08.025

Smith HO, Kohorn E, Cole LA. Choriocarcinoma and gestational trophoblastic disease. Obstet Gynecol Clin North Am 2005;32(4):661–84

Hassadia A, Kew FM, Tidy JA, Wells M, Hancock BW. Ectopic gestational trophoblastic disease: a case series review. J Reprod Med 2012;57(7–8):297–300

McGrath S, Short D, Harvey R et al. The management and outcome of women with post-hydatidiform mole ‘low-risk’ gestational trophoblastic neoplasia, but hCG levels in excess of 100 000 IU l(-1). Br J Cancer 2010; 102: 810–814

M. J. Seckl, N. J. Sebire, R. A. Fisher, F. Golfier, L. Massuger & C. Sessa. Gestational trophoblastic disease: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Annals of Oncology 24 (Supplement 6): vi39–vi50, 2013.

Abu-Rustum NR, Yashar CM, Bean S, Bradley K, Campos SM et al. Gestational Trophoblastic Neoplasia, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 Nov 1;17(11):1374-1391. doi: 10.6004/jnccn.2019.0053.

Jun, F., Peng, Z., Zhang, Y., & Shi, D. (2020). Quantitative proteomic analysis identifies novel regulators of methotrexate resistance in choriocarcinoma. Gynecologic Oncology. doi:10.1016/j.ygyno.2020.01.013

Newlands ES, Mulholland PJ, Holden L, Seckl MJ, Rustin GJ (2000) Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors. J Clin Oncol 18: 854-859.

Alifrangis C, Agarwal R, Short D et al. EMA/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposidecisplatin and genetic analysis. J Clin Oncol 2013; 31: 280–286.

Chan Wah Hak, C., Coyle, C., Kocache, A. et al. Emergency Etoposide-Cisplatin (Em-EP) for patients with germ cell tumours (GCT) and trophoblastic neoplasia (TN). BMC Cancer 19, 770 (2019). https://doi.org/10.1186/s12885-019-5968-7